Management Team

Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer

Robert L. Coffman, PhD, is Senior Vice President and Chief Scientific Officer of Dynavax Technologies Corporation in Berkeley, CA. Prior to joining Dynavax in 2000, Dr. Coffman was a founding member of the DNAX Research Institute in Palo Alto, CA. Dr. Coffman has authored over 200 scientific publications, is a member of the National Academy of Sciences and the American Academy of Microbiology, and has received a number of prestigious awards for his work. With colleague Dr. Tim Mosmann, he defined the two principal subtypes of helper T cells, termed Th1 and Th2 cells, and demonstrated the central relationship between their differences in cytokine expression and function. Dr .Coffman defined basic mechanisms of T-cell regulation in asthma and infectious and parasitic diseases, and demonstrated the central role of regulatory CD4+ T cells in preventing inflammatory bowel disease. At Dynavax, Dr. Coffman has pioneered the development of agonists and antagonists for Toll-like receptors, key recognition receptors in innate immunity.

Steven N. Gersten Senior Vice President, General Counsel, Secretary and Chief Ethics and Compliance Officer

Steven N. Gersten is Senior Vice President, General Counsel, Secretary and Chief Ethics and Compliance Officer. He joined Dynavax in 2015 as Vice President, General Counsel, and Chief Ethics and Compliance Officer. Prior to joining Dynavax, he served as global Vice President and Ethics and Compliance Officer at AbbVie, where he helped build the compliance program and organization. From 2002 to 2013, he was employed by Abbott Laboratories, where he served as global Vice President and Chief Regulatory and Compliance Counsel for all businesses, and global Vice President and General Counsel to several business units, setting global legal strategies and functional plans as well as overseeing the internal legal organization and external counsel. Prior to joining Abbott, Mr. Gersten held various positions of increasing responsibility with the U.S. Department of Justice (where he brought enforcement cases on behalf of the FDA), the law firms Howrey and Simon, and Shea and Gould, and with the U.S. Attorney’s Office in Washington, D.C. Mr. Gersten holds a JD degree from the Boston University School of Law and a BS degree in Finance from Boston University School of Business.

Robert Janssen Chief Medical Officer and Senior Vice President, Clinical Development

Dr. Janssen was appointed Chief Medical Officer and Vice President, Clinical Development in July 2013. He most recently served as Dynavax's Vice President, Medical Affairs since November 2012 and was previously Senior Director, Clinical Development at Dynavax from 2010 through 2012, during which time he was extensively involved with Phase 3 clinical development of HEPLISAV-B and its US and European licensing applications. Prior to joining Dynavax, Dr. Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of physician and health care provider education focused on HIV and hepatitis B therapies. Until 2008, Dr. Janssen spent 23 years at the US Centers for Disease Control and Prevention (CDC), most recently as the Director of the Division of HIV/AIDS Prevention from 2000 to 2008. Under his leadership, CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of pre-exposure prophylaxis for HIV. Dr. Janssen received a Bachelor of Arts degree with Honors in Humanities from Stanford University and his M.D. degree from the University of Southern California. He is a neurologist with training in virology at the University of Pennsylvania. Dr. Janssen has been the beneficiary of numerous honors and awards during his career. He has published over 130 scientific articles in a variety of journals and has served as a reviewer for leading scientific journals.

David Novack Senior Vice President, Operations

Mr. Novack has been the Senior Vice President of Operations for Dynavax since 2013, and has led the company’s technical operations, supply chain, and quality teams through FDA approval, launch and commercialization of HEPLISAV-B. Mr. Novack has more than 30 years of relevant industry experience, with more than 20 years of direct vaccine industry experience. Prior to Dynavax, Mr. Novack was at Novartis where he served in various roles, including Global Head of Technical Operations and Supply Chain for Diagnostics, and Global Head of Manufacturing Strategy for Vaccines. Prior to Novartis, Mr. Novack held management positions at MedImmune and Lederle Laboratories (now Pfizer). Mr. Novack received a B.S. in Biology from the State University of New York at Albany, and an M.B.A. from Columbia University.

Michael S. Ostrach Senior Vice President, Chief Financial Officer and Chief Business Officer

Mr. Ostrach joined Dynavax in 2006 as Vice President, Chief Business Officer and General Counsel and became Principal Financial Officer in 2013 and Chief Financial Officer in 2015. From 2005 to 2006, he was Chief Operating Officer, Chief Financial Officer and General Counsel at Threshold Pharmaceuticals. From 1997 to 2004, Mr. Ostrach was at Kosan Biosciences, most recently as President and Chief Operating Officer. Mr. Ostrach began his corporate career at Cetus Corporation, where he served in several capacities between 1981 and 1991, initially as general counsel and finally as Senior Vice President of corporate affairs and General Counsel. Following the acquisition of Cetus by Chiron Corporation in 1991, Mr. Ostrach became President of Chiron Technologies. He holds a B.A. from Brown University and a J.D. from Stanford Law School.

Ryan Spencer Senior Vice President, Commercial

Ryan Spencer, joined Dynavax in 2005 and currently serves as the Senior Vice President of Commercial. Throughout his time at Dynavax, Mr. Spencer has held a variety of positions with increasing responsibility, building from a foundation in corporate finance to business strategy and investor relations, culminating in his current role leading the launch and commercialization of HEPLISAV-B. Prior to joining Dynavax, Mr. Spencer was the Assistant Controller at QRS Corporation, a publicly-held technology company, and was a member of the audit practice at Ernst & Young. Mr. Spencer earned a B.A. in Business Economics from University of California, Santa Barbara.

Jeff Coon Senior Vice President, Human Resources and Corporate Services

Mr. Coon joined Dynavax in 2019 as Senior Vice President, Human Resources and Corporate Services. From 2017 to 2019, he was the Senior Vice President of Human Resources at FivePrime Therapeutics. From 2011 to 2017, Mr. Coon was at Depomed, Inc., where he served as Senior Vice President, Human Resources and Administration. Mr. Coon has held senior-level Human Resources positions with several life sciences companies over his thirty plus year career, including Johnson & Johnson, PDL BioPharm and Exelixis. He received a M.S. in Human Resources Management from Golden Gate University and a B.A. in Public Administration from the California State University-Long Beach.